Who is sponsoring NCT03381170?

NCT03381170 is sponsored by TG Therapeutics, Inc..

What drugs are being tested in NCT03381170?

Interventions in NCT03381170: Ublituximab.

What condition does NCT03381170 study?

NCT03381170 studies Relapsing Remitting Multiple Sclerosis.

Is NCT03381170 still recruiting?

NCT03381170 is currently completed. Last updated 21 December 2022.

Last reviewed 2022-12-21 · How we verify

NCT03381170

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Extension of the TG1101-RMS201 Trial

Completed Phase 2 Last updated 21 December 2022

What this trial tests

Phase 2 trial testing Ublituximab in Relapsing Remitting Multiple Sclerosis in 48 participants. Completed in 11 November 2022.

Timeline

1 June 2017

Primary endpoint
11 November 2022

11 November 2022

Quick facts

Lead sponsor	TG Therapeutics, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	1 June 2017
Primary completion	11 November 2022
Estimated completion	11 November 2022
Sites	8 locations across United States

Drugs / interventions tested

Ublituximab — full drug profile →

Conditions studied

Relapsing Remitting Multiple Sclerosis — all drugs for Relapsing Remitting Multiple Sclerosis →

Sponsor

TG Therapeutics, Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Relapsing Remitting Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
Frisch ES, Pretzsch R, Weber MS. · · 2021 · cited 22× · PMID 33880738 · DOI 10.1007/s13311-021-01048-z
Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review.
Hiramatsu K, Maeda H. · · 2024 · cited 1× · PMID 38708586 · DOI 10.1111/cts.13794

Verify or expand the search:

Other trials of Ublituximab

Trials testing the same drug.

NCT07220252 — Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis · Phase 2, PHASE3 · not yet recruiting
NCT06864936 — Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis · NA · not yet recruiting
NCT07503873 — A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection · Phase 2 · not yet recruiting
NCT07225361 — Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis · Phase 4 · recruiting
NCT06629428 — Effects of Ublituximab on Motor Functions in Multiple Sclerosis · EARLY_PHASE1 · recruiting

Other recruiting trials for Relapsing Remitting Multiple Sclerosis

Currently open trials in the same condition.

NCT06796504 — The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study · NA · recruiting
NCT05949580 — Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple · recruiting
NCT06282081 — Serum Neurofilament Light in Multiple Sclerosis · active not recruiting
NCT05327322 — Functional Outcomes From Diets in Multiple Sclerosis · NA · active not recruiting
NCT05171972 — Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment · active not recruiting

Other TG Therapeutics, Inc. trials

Trials by the same sponsor.

NCT07220252 — Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis · Phase 2, PHASE3 · not yet recruiting
NCT07503873 — A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection · Phase 2 · not yet recruiting
NCT07211633 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ub · Phase 3 · recruiting
NCT06680037 — A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders · Phase 1 · recruiting
NCT06433752 — A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Mult · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03381170 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TG Therapeutics, Inc.
Last refreshed: 21 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03381170.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing